Recent Tendency of Therapeutic Medical Agents for Diabetic Peripheral Neuropathic Pain
DOI:
https://doi.org/10.17140/DROJ-6-e015Keywords:
Neuropathic pain; Pregabalin, Mirogabalin; Duloxetine hydrochloride, Diabetic peripheral neuropathic pain (DPNP).Abstract
Recently, elder patients tend to have neuropathic pain such as lower back and joints pain, stiff shoulders, besides diabetic
neuropathy. Typical peripheral neuropathic pain includes diabetic peripheral neuropathic pain (DPNP), postherpetic neuralgia
(PHN) and chronic pain due to herniated disc. Three analgesic agents are described. Pregabalin (Lyrica®) has been prevalent
worldwide. However, it has been provided for several diseases for off-label administration, which has been one of the clinical
problems.Mirogabalin (Tarlige®) has revealed efficacy for DPNP in a dose-dependent manner. Duloxetine hydrochloride (Cymbalta
®) has efficacy for pain and also depression as serotonin and noradrenaline reuptake inhibitor (SNRI).
References
Imagama S, Ando K, Kobayashi K, Seki T, Hamada T, Machino M, et al. Shoulder pain has most impact on poor quality of life among various types of musculoskeletal pain in middle-aged and elderly people: Yakumo study. Modern Rheumatology. 2019; 1-5. doi: 10.1080/14397595.2019.1623364
Bannister K, Sachau J, Baron R, Dickenson AH. Neuro-pathic pain: Mechanism-based therapeutics. Ann Rev Pharmacol Toxicol. 2020; 60(1): 257-274. doi: 10.1146/annurev-pharm-tox-010818-021524
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017; 3: 17002. doi: 10.1038/nrdp.2017.2
Miller C, Williams M, Heine P, Williamson E, O’connell N. Current practice in the rehabilitation of complex regional pain syndrome: A survey of practitioners. Disability and Rehabilitation. 2017; 41(7): 1-7. doi: 10.1080/09638288.2017.1407968
Schjerning O, Rosenzweig M, Pottegård A, Damkier P, Nielsen J. Abuse potential of pregabalin. CNS Drugs. 2016; 30(1): 9-25. doi: 10.1007/s40263-015-0303-6
Goodman CW, Brett AS. Gabapentin and pregabalin for pain — is increased prescribing a cause for concern? New Eng J Med. 2017; 377(5): 411-414. doi: 10.1056/nejmp1704633
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019; 179(5): 695-701. doi: 10.1001/jamainternmed.2019.0086
Vickers-Smith R, Sun J, Charnigo RJ, Lofwall MR, Walsh SL, Havens JR. Gabapentin drug misuse signals: A pharmacovigi-lance assessment using the FDA Adverse Event Reporting Sys-tem. Drug and Alcohol Dependence. 2019; 206: 107709. doi: 107709. doi:10.1016/j.drugalcdep.2019.107709
Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Ya-mamura N, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018; 365(3): 573-582. doi: 10.1124/jpet.117.247551 Editorial | Volume 6 | Number 1| Bando H
VinikA, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D. Efficacy and safety of mirogabalin (DS-5565) for the treat-ment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo- and active comparator–controlled, adap-tive proof-of-concept phase 2 study. Diabetes Care. 2014; 37(12): 3253-3261. doi: 10.2337/dc14-1044
Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Miro-gabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Journal of Diabetes Investigation. 2019; 10(5): doi: 10.1111/jdi.13013
Alam U, Sloan G, Tesfaye S. Treating pain in diabetic neuropa-thy: Current and developmental drugs. Drugs. 2020; 80(4): 363- 384. doi: 10.1007/s40265-020-01259-2
Mendell J, Levy-Cooperman N, Sellers E, Vince B, Kelsh D, Lee J, et al. Abuse potential of mirogabalin in recreation-al polydrug users. Therapeutic Advances in Drug Safety. 2019; 10: 204209861983603. doi: 10.1177/2042098619836032
Wattiez AS, Dupuis A, Privat AM, Chalus M, Chapuy E, Aissouni Y, et al. Disruption of 5-HT 2A -PDZ protein inter-action differently affects the analgesic efficacy of SSRI, SNRI and TCA in the treatment of traumatic neuropathic pain in rats. Neuropharmacology. 2017; 125: 308-318. doi: 10.1016/j.neuro-pharm.2017.07.034
Weng C, Xu J, Wang Q, Lu W, Liu Z. Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: A system-atic review and meta-analysis. Osteoarthritis and Cartilage. 2020; doi: 10.1016/j.joca.2020.03.001
Shelton RC. Serotonin and norepinephrine reuptake inhibi-tors. In: Macaluso M, Preskorn S, eds. Antidepressants. Experi-mental Pharmacology, vol 250. New York, USA: Springer, Cham; 2018: 145-180. doi: 10.1007/164_2018_164
De Oliveira Filho GR, Kammer RS, dos Santos H de C. Du-loxetine for the treatment acute postoperative pain in adult pa-tients: A systematic review with meta-analysis. Journal of Clinical Anesthesia. 2020; 63: 109785. doi: 10.1016/j.jclinane.2020.109785
Ruiz-Negrón N, Menon J, King JB, Ma J, Bellows BK. Cost-ef-fectiveness of treatment options for neuropathic pain: A system-atic review. Pharmaco Economics. 2019; 37: 669-688. doi: 10.1007/ s40273-018-00761-6
National Institute for Health and Care Excellence. Neuro-pathic pain in adults: pharmacological management in non-spe-cialist settings. NICE Clin Guidel Webn site. https://www.nice. org.uk/guidance/cg173. 2013. Accesed April 19, 2020.
Hadley GR, Gayle JA, Ripoll J, Jones MR, Argoff CE, Kaye RJ, et al. Post-herpetic neuralgia: A Review. Curr Pain Headache Rep. 2016; 20(3): 17. doi: 10.1007/s1191 6-016-0548-x e3
Pop-BusuiR, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136- 154. doi: 10.2337/dc16-2042
SelvarajahD, Petrie J, White D, Julious S, Bortolami O, Coo-per C, et al. Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIngneurOpathicpaiN in Diabe-tes Mellitus (OPTION-DM): Study protocol for a randomised Submit your article to this journal | https://openventio.org/submit-manuscript/ e4 Bando H controlled trial. BMS. 2018; 19: 578(2018): 1-16. doi: 10.1186/ s13063-018-2959-y
Critchlow S, Hirst M, Akehurst R, Phillips C, Philips Z, Sullivan W, et al. A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: Variation in prac-tice, key challenges, and recommendations for the future. J Med Econ. 2017; 20(2): 129-139. doi: 10.1080/13696 998.2016.12296 Editorial | Volume 6 | Number 1|
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
